The Hospital will use SOPHiA DDM™ to enhance
its testing and research of blood cancers
BOSTON and ROLLE, Switzerland, June 13,
2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native healthcare technology company and a leader in
data-driven medicine, today announced that Kepler Uniklinikum,
Austria's second largest hospital,
is live on SOPHiA GENETICS' platform. The hospital will use the
SOPHiA DDM™ Platform to advance its next-generation sequencing
(NGS) testing and diagnostics of blood-related cancers.
Kepler Uniklinikum, which has 1,800 beds, is the central
healthcare provider for Upper Austria. The hospital will implement
the SOPHiA DDM™ Platform across its medical and chemical
laboratory locations to deepen its in-house NGS testing
capabilities and expand its offerings to its patients, specifically
for those faced with blood cancers and disorders.
Cancer is the second most common cause of death in Austria, with about 42,000 people diagnosed
with cancer each year.1 Additionally, on a global scale,
blood cancers are the fifth most common type of cancer in the
world.2 Advances in diagnostics and treatment of blood
cancers depend on timely, cost-effective, and reliable sequencing
data. The SOPHiA DDM™ Platform uses NGS to target key variants from
FFPE, blood, or bone marrow samples, helping lead to fast and
accurate detection of variants associated with the disease. The
SOPHiA DDM™ Platform is specifically designed to compute a wide
array of genomic variants and continually hones its machine
learning algorithms to detect genomic variants associated with rare
and challenging cases.
"Kepler Uniklinikum's implementation of the SOPHiA DDM™ Platform
will help progress the use of data-driven medicine throughout
Austria by ensuring their patients
receive the most advanced and accurate testing," said Kevin
Puylaert, Managing Director, EMEA, SOPHiA GENETICS. "This testing
will not only help the local population but will provide valuable
insights and data to support others using the SOPHiA DDM™ Platform
around the world."
The SOPHiA DDM™ Platform delivers results that are nearly 100
percent reproducible to provide consistent inter- and intra-run
results, ensuring stable and trustworthy sequencing data.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare
technology company on a mission to expand access to
data-driven medicine by using AI to deliver world-class care to
patients with cancer and rare disorders across the globe.
It is the creator of the SOPHiA DDM™
Platform, which analyzes complex genomic and multimodal
data and generates real-time, actionable insights for a broad
global network of hospital, laboratory, and biopharma
institutions. For more information,
visit SOPHiAGENETICS.COM and connect with us
on LinkedIn.
SOPHiA DDM™ for Lymphoid Malignancies is available as a
CE-IVD product for In Vitro Diagnostic Use in Europe and Turkey. The information in this press release
is about products that may or may not be available in different
countries and, if applicable, may or may not have received approval
or market clearance by a governmental regulatory body for different
indications for use. Please contact support@sophiagenetics.com to
obtain the appropriate product information for your country of
residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements
that constitute forward-looking statements. All statements other
than statements of historical facts contained in this press
release, including statements regarding our future results of
operations and financial position, business strategy, products, and
technology, as well as plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements are based on our management's beliefs and assumptions
and on information currently available to our management. Such
statements are subject to risks and uncertainties, and actual
results may differ materially from those expressed or implied in
the forward-looking statements due to various factors, including
those described in our filings with the U.S. Securities and
Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
1
https://ascopost.com/issues/october-25-2022/incidence-and-cancer-related-mortality-in-austria/
2
https://www.worldwidecancerresearch.org/news-opinion/2022/september/blood-cancer-everything-you-need-to-know/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-kepler-uniklinikum-is-live-on-sophia-ddm-platform-302171344.html
SOURCE SOPHiA GENETICS